Stocks of Aurobindo Pharma surged 6.5 per cent today as the company received approval from the US health regulator to manufacture and market Sildenafil injection, used for treating pulmonary arterial hypertension, in the American market.
The scrip jumped 6.19 per cent to settle the day at Rs 1,324.95 on the BSE. In intra-day, it gained 6.59 per cent to Rs 1,330, its 52-week high.
On the NSE, the scrip ended at Rs 1,328, up 6.46 per cent.
The company has received approval from the US Food and Drug Administration (USFDA) to manufacture and market Sildenafil injection in the US market, Aurobindo Pharma had said in a statement on Saturday.
The company's product is a generic version of Pfizer's Revatio injection.
Sildenafil injection is indicated for the treatment of adult patients with pulmonary arterial hypertension who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.
